Gut Microbiome and Cutaneous Oncology

In a presentation on the impact of the gut microbiome in cutaneous oncology, Allen Zoe, an Associate Professor of Dermatology at Northwestern, explores the microbiome's role in skin cancers, particularly melanoma and cutaneous T-cell lymphoma (CTCL). Studies reveal that melanoma patients exhibit lower gut bacterial diversity, with notable shifts in microbial populations, including higher levels of Fusobacterium and lower levels of Ruminococcus. Fusobacterium has been linked to carcinogenesis in colorectal cancer and is also found in melanoma. In CTCL, the gut microbiome demonstrates a dysbiotic profile, characterized by a reduction in beneficial short-chain fatty acid-producing bacteria, leading to increased chronic inflammation and immunological changes that support tumor growth. Antibiotic treatments have shown potential in reducing disease severity in CTCL patients. The gut microbiome's alterations also correspond with immune responses and treatment outcomes, highlighting its significant influence on cancer biology. Overall, the presentation emphasizes the gut microbiome's complex interactions with skin cancers and the potential for therapeutic strategies targeting microbial compositions to enhance treatment efficacy.